Phase II study of antineoplastons A10 and AS2-1 in adult patients with oligodendroglioma
Latest Information Update: 03 Nov 2021
Price :
$35 *
At a glance
- Drugs Antineoplaston-A10 (Primary) ; Antineoplaston-AS2-1 (Primary)
- Indications Glioma
- Focus Therapeutic Use
- 21 Jul 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 11 Apr 2008 The expected completion date for this trial is now 1 Dec 2011, according to clinicaltrials.gov.
- 19 Aug 2005 New trial record.